Zhang Yong, Jiang Peixin, Ye Min, Kim Sung-Hoon, Jiang Cheng, Lü Junxuan
Department of Biomedical Sciences and Cancer Biology Center, Texas Tech University Health Sciences Center School of Pharmacy, 1300 S. Coulter, Amarillo, TX 79106, USA.
Int J Mol Sci. 2012 Oct 22;13(10):13621-66. doi: 10.3390/ijms131013621.
Tanshinones are a class of abietane diterpene compound isolated from Salvia miltiorrhiza (Danshen or Tanshen in Chinese), a well-known herb in Traditional Chinese Medicine (TCM). Since they were first identified in the 1930s, more than 40 lipophilic tanshinones and structurally related compounds have been isolated from Danshen. In recent decades, numerous studies have been conducted to investigate the isolation, identification, synthesis and pharmacology of tanshinones. In addition to the well-studied cardiovascular activities, tanshinones have been investigated more recently for their anti-cancer activities in vitro and in vivo. In this review, we update the herbal and alternative sources of tanshinones, and the pharmacokinetics of selected tanshinones. We discuss anti-cancer properties and identify critical issues for future research. Whereas previous studies have suggested anti-cancer potential of tanshinones affecting multiple cellular processes and molecular targets in cell culture models, data from in vivo potency assessment experiments in preclinical models vary greatly due to lack of uniformity of solvent vehicles and routes of administration. Chemical modifications and novel formulations had been made to address the poor oral bioavailability of tanshinones. So far, human clinical trials have been far from ideal in their design and execution for the purpose of supporting an anti-cancer indication of tanshinones.
丹参酮是一类从丹参(中药中一种著名的草药)中分离出的松香烷二萜类化合物。自20世纪30年代首次被鉴定以来,已从丹参中分离出40多种亲脂性丹参酮及结构相关化合物。近几十年来,人们对丹参酮的分离、鉴定、合成及药理学进行了大量研究。除了已被充分研究的心血管活性外,丹参酮最近还在体外和体内的抗癌活性方面得到了研究。在本综述中,我们更新了丹参酮的草药来源和替代来源,以及所选丹参酮的药代动力学。我们讨论了抗癌特性,并确定了未来研究的关键问题。尽管先前的研究表明丹参酮在细胞培养模型中具有影响多种细胞过程和分子靶点的抗癌潜力,但由于溶剂载体和给药途径缺乏一致性,临床前模型中体内效能评估实验的数据差异很大。已进行化学修饰和新型制剂研发以解决丹参酮口服生物利用度差的问题。到目前为止,就支持丹参酮的抗癌适应症而言,人体临床试验在设计和实施方面远不理想。